Search clinical trials for: AZD1236

Total 107 results

AstraZeneca

Completed

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients (CERA)

Chronic Obstructive Pulmonary Disease

Bulgaria, Germany, Hungary, Finland, Slovakia
AstraZeneca

Completed

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients (BICO)

Chronic Obstructive Pulmonary Disease

Denmark, Finland, Norway, Netherlands
AstraZeneca

Completed

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

Healthy Volunteer

Japan
AstraZeneca

Withdrawn

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis (CYBER)

Cystic Fibrosis

Netherlands, Poland, Spain, Canada
University of Edinburgh
NHS Lothian

Completed

Imaging FIB ONE in the Human Lung Using Endomicroscopy (FIB ONE)

Fibrosis | Lung Cancer

United Kingdom
AstraZeneca

Terminated

Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects

Healthy

United Kingdom
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

Dilated Cardiomyopathy

United States
Imperial College London
AstraZeneca; University of Oxford

Active, not recruiting

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers (COVAXAER01)

Covid19 | SARS-CoV-2 Infection

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Hypercholesterolemia

United States
AstraZeneca

Completed

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

Glucose Lowering

United States
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca
Parexel

Terminated

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

End Stage Renal Disease

Poland
AstraZeneca

Completed

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Advanced Solid Malignancies | Malignant Lymphoma

United Kingdom, Japan
AstraZeneca

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients

Acute Myeloid Leukemia

United States, Canada
AstraZeneca

Completed

To Evaluate the Bioavailability of a Tablet of AZD1656

Type 1 Diabetes

United States
AstraZeneca

Completed

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) (ADME)

Type II Diabetes Mellitus

United States
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

Sensitivity in Esophagus

Denmark, Sweden
AstraZeneca

Completed

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes (MAD)

Type 2 Diabetes

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers (SAD)

Healthy

Sweden
AstraZeneca

Completed

Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses

Healthy

Japan
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386 (MAD)

Chronic Pain

United Kingdom
AstraZeneca
Parexel

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States, Germany
St George Street Capital

Completed

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

Covid19

Czechia, Romania, United Kingdom
AstraZeneca

Terminated

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee (OA19)

Pain

Bulgaria, Poland, Hungary, Finland, Canada, Slovakia, Japan
AstraZeneca

Completed

A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions

Healthy

Sweden
AstraZeneca

Completed

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Type 2 Diabetes

Japan
Queen Mary University of London
AstraZeneca

Active, not recruiting

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce (ADOPTION)

Diabetes Mellitus, Type 2 | End Stage Renal Disease | Type 2 Diabetes | Renal Transplant | Kidney Transplant; Complications

United Kingdom
AstraZeneca

Completed

AZD1386 Japanese Multiple Ascending Dosing Study (JMAD)

Chronic Pain

Japan
AstraZeneca
Parexel

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

Dyslipidemia

United States
AstraZeneca
RTI Health Solutions

Completed

EU Secondary Data Post-Authorisation Safety Study of AZD1222 (D8111R00006)

COVID-19, Vaccine Adverse Events of Special Interest

Netherlands, Spain, United Kingdom
AstraZeneca
Covance; Iqvia Pty Ltd

Withdrawn

AZD1222 Vaccine for the Prevention of COVID-19

COVID-19

Russian Federation
AstraZeneca

Completed

Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.

Adult ADHD

United States
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Federal University of Espirito Santo
Instituto René Rachou/Fiocruz; Escola Nacional de Saúde Pública Sérgio Arouca... and other collaborators

Recruiting

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

SARS-CoV-2

Brazil
AstraZeneca

Completed

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Type II Diabetes

United States
AstraZeneca

Completed

Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386

Pain

United Kingdom
Chang Gung Memorial Hospital

Recruiting

Immunogenicity of COVID-19 Vaccine on Heterologous Schedule

Healthy | Covid-19 | Vaccine | Immunogenicity | Reactogenicity

Taiwan
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

Healthy Participants

United States, United Kingdom, Germany
AstraZeneca

Completed

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia (SOLANO)

Hyperlipidaemia

Denmark, Netherlands, Spain, Czechia, United States, Slovakia, Hungary, Poland
AstraZeneca

Completed

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Type 2 Diabetes

United States
AstraZeneca

Completed

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Type 2 Diabetes

United States
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject

Healthy

Japan
AstraZeneca

Completed

Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea

Type II Diabetes Mellitus

United States
AstraZeneca

Completed

Esophageal Hypersensitivity Study in Healthy Volunteers

Pain | Esophageal Sensitivity

Sweden, Denmark
Albert B. Sabin Vaccine Institute
Stanford University; Aga Khan University; Oswaldo Cruz Foundation

Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

COVID-19

Brazil, Pakistan
AstraZeneca

Completed

Formulation and Food Effect Study of AZD1386 in Healthy Volunteers

Pharmacokinetics
AstraZeneca

Terminated

Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain (AVANT)

Pain | Neuropathic Pain

France, United Kingdom, Canada, Denmark

3

Subscribe